Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Asthma-I: Introduction

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...

Asthma-III: Symptoms and Complications

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Differences in the peripheral blood immune landscape between early-onset and late-onset colorectal cancer.

Frontiers in immunology·2026

Same author

Differences in the peripheral blood immune landscape between early-onset and late-onset colorectal cancer.

Frontiers in immunology·2025

Same author

Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma.

Frontiers in immunology·2025

Same author

Genome-wide Association Study of Asthma Exacerbations in the Spanish Population.

Archivos de bronconeumologia·2025

Same author

Signature Proteins in Small Extracellular Vesicles of Granulocytes and CD4<sup>+</sup> T-Cell Subpopulations Identified by Comparative Proteomic Analysis.

International journal of molecular sciences·2024

Same author

Exploring CD26<sup>-/lo</sup> subpopulations of lymphocytes in asthma phenotype and severity: A novel CD4<sup>+</sup> T cell subset expressing archetypical granulocyte proteins.

Allergy·2024

Search research articles

Related Experiment Video

Updated: Mar 15, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

CD26 and Asthma: a Comprehensive Review.

Juan J Nieto-Fontarigo¹, Francisco J González-Barcala^1,2, Esther San José³

¹Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), University of Santiago de Compostela (USC), Santiago de Compostela, Spain.

Clinical Reviews in Allergy & Immunology

|August 27, 2016

Summary

This review explores CD26, a serine protease, and its potential role in asthma pathogenesis. Understanding CD26

Keywords:

Asthma CD26 CD26 inhibitors Cytokines and chemokines DPP4 sCD26

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Published on: September 20, 2019

Related Experiment Videos

Last Updated: Mar 15, 2026

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Published on: September 20, 2019

Area of Science:

Immunology
Genetics
Biochemistry

Background:

Asthma is a chronic inflammatory airway disease influenced by genetic and environmental factors.
Serine proteases, particularly the S9 family, are implicated in asthma due to their role in processing key inflammatory mediators.
CD26 (dipeptidyl peptidase 4) and DPP10 are S9 family members located on chromosome 2 with potential links to asthma.

Purpose of the Study:

To review current knowledge on CD26 and its functions.
To explore the implications of CD26 in asthma pathogenesis.
To consider CD26 inhibitory therapy in light of observed side effects in related conditions.

Main Methods:

Literature review of studies on CD26, asthma, and related inflammatory processes.
Analysis of genetic associations and biochemical functions of CD26.
Examination of clinical observations regarding CD26 inhibition.

Main Results:

CD26 is a versatile enzyme involved in processing proline-adjacent peptide bonds, relevant to asthma mediators.
CD26 and DPP10 are serine proteases encoded by genes on chromosome 2, suggesting a specific genetic link to asthma.
CD26 inhibitory therapy in type II diabetes mellitus patients showed secondary effects, including viral nasopharyngitis, relevant to asthma risk.

Conclusions:

CD26 plays a multifaceted role in immune regulation and inflammation, potentially contributing to asthma.
Further research into CD26's specific mechanisms in asthma is warranted.
Understanding CD26's impact is crucial for developing targeted asthma therapies and managing potential side effects of inhibitors.